EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DNA Methylation Profiling in IDH‐Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation

Pietro Tralongo iD, Gabriele Ricciardi iD, Mariagiovanna Ballato iD, Vincenzo Fiorentino iD, Valeria Zuccalà iD, Giorgia Castellani iD, Quintino Giorgio D'Alessandris iD, Guido Fadda, Lucia Ricci-Vitiani, Maria Caffo iD, Maurizio Martini iD

Neuropathology and Applied Neurobiology · 2026

DOI: 10.1111/nan.70100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuropathology and Applied Neurobiology, 2026. Verfasst von Pietro Tralongo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: DNA Methylation, Isocitrate Dehydrogenase, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) define a major subgroup of adult‐type diffuse gliomas and induce accumulation of D‐2‐hydroxyglutarate, resulting in extensive DNA and histone methylation changes. This epigenetic reprogramming underlies the glioma CpG island methylator phenotype (G‐CIMP) and contributes to tumour lineage, differentiation state and clinical behaviour. DNA methylation profiling has consequently evolved from a research tool into an important ancillary method for CNS tumour classification, molecular subclassification and copy‐number analysis. This narrative review examines the biological basis, analytical platforms and clinical applications of DNA methylation profiling in IDH‐mutant gliomas. Particular attention is given to the distinction between research‐defined G‐CIMP‐high and G‐CIMP‐low states and classifier‐defined lower‐grade and high‐grade methylation subclasses. High‐grade signatures, including A_IDH_HG and G‐CIMP‐low, are associated with adverse genomic features and outcome but should not be considered interchangeable or used in isolation to assign CNS WHO grade. Their interpretation requires integration with histology and established molecular criteria, including homozygous CDKN2A/B deletion. The review also discusses array‐based profiling, emerging Nanopore and long‐read approaches, computational quality control, and the integration of methylation data with genomic and transcriptomic alterations. Longitudinal studies indicate that a subset of IDH‐mutant astrocytomas undergoes methylation loss, copy‐number accumulation and altered cell‐state differentiation during progression, although these changes are not universal. The clinical relevance of MGMT promoter methylation is more context‐dependent than in IDH‐wildtype glioblastoma. Moreover, the INDIGO trial established the clinical activity of mutant IDH inhibition in selected Grade 2 gliomas but did not validate methylation class as a predictive biomarker or demonstrate complete epigenetic reversal. Emerging applications, including single‐cell and spatial epigenomics, tumour microenvironment deconvolution and CSF methylation profiling, remain investigational. Overall, DNA methylation profiling is most valuable when used as integrated diagnostic and risk‐stratification evidence within the complete histological, genomic and clinical context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationIsocitrate DehydrogenaseGliomaBrain NeoplasmsHumansMutationNeoplasm GradingEpigenesis, Genetic

Stichwörter der Autor:innen

DNA methylationIDH mutationglioma CpG island methylator phenotypemolecular classificationprognostic biomarkers

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanIDH2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
  • Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
  • Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, Rome, Italy.
  • Department of Neurosurgery, Fondazione Policlinico Universitario a. Gemelli IRCCS, Largo a. Gemelli, 8, Rome, Italy.
  • Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Neurosurgery, University of Messina, Messina, Italy.

ORCID-Profile: Pietro Tralongo, Gabriele Ricciardi, Mariagiovanna Ballato, Vincenzo Fiorentino, Valeria Zuccalà, Giorgia Castellani, Quintino Giorgio D'Alessandris, Maria Caffo, Maurizio Martini

Förderung

  • Fondazione AIRC per la ricerca sul cancro ETS
  • Ministero della Salute

Zitieren

APA

Tralongo, P., Ricciardi, G., Ballato, M., Fiorentino, V., Zuccalà, V., Castellani, G., D'Alessandris, Q. G., Fadda, G., Ricci-Vitiani, L., Caffo, M., & Martini, M. (2026). DNA Methylation Profiling in IDH‐Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70100

Vancouver

Tralongo P, Ricciardi G, Ballato M, Fiorentino V, Zuccalà V, Castellani G, et al. DNA Methylation Profiling in IDH‐Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation. Neuropathology and Applied Neurobiology. 2026. doi:10.1111/nan.70100

BibTeX
@article{Tralongo2026,
  author = {Tralongo, Pietro and Ricciardi, Gabriele and Ballato, Mariagiovanna and Fiorentino, Vincenzo and Zuccalà, Valeria and Castellani, Giorgia and D'Alessandris, Quintino Giorgio and Fadda, Guido and Ricci-Vitiani, Lucia and Caffo, Maria and Martini, Maurizio},
  title = {DNA Methylation Profiling in IDH‐Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2026},
  doi = {10.1111/nan.70100}
}
Kostenlos starten →